Gene therapy for sickle cell disease: An update

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Sickle cell disease (SCD) is a prevalent, life-threatening monogenic disorder impacting millions globally.
• Allogeneic hematopoietic stem cell transplantation is the sole cure but faces donor limitations and significant risks.
• Existing therapies necessitate exploration of alternative treatment strategies.

Purpose of the Study:

• To review current and emerging therapeutic strategies for sickle cell disease.
• To highlight advancements in gene therapy and genome engineering for SCD treatment.
• To discuss the potential and challenges of novel genetic approaches.

Main Methods:

• Review of ex vivo gene therapy approaches, including globin gene addition.
• Analysis of recent clinical trial data for gene addition therapies.
• Exploration of genome engineering tools like CRISPR/Cas9 for genetic correction.
• Investigation of induced pluripotent stem cells and patient-derived hematopoietic stem cells.

Main Results:

• Ex vivo gene therapy via globin gene addition shows encouraging clinical trial results.
• Advances in understanding erythropoiesis and globin switching present new therapeutic targets.
• Genome engineering tools offer potential for direct genetic correction of SCD.

Conclusions:

• Gene therapy and genome editing represent promising future treatments for sickle cell disease.
• Further research is crucial to address safety and efficacy before clinical translation of gene editing techniques.
• Continued investigation into molecular pathways of erythropoiesis may yield novel therapeutic insights.